Mallinckrodt Completes Stannsoporfin New Drug Application Filing

8 years ago

by David Miller

960 Views

Written by David Miller

STAINES-UPON-THAMES, United Kingdom, Jan. 4, 2018 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has successfully completed the rolling submission of a New Drug Application (NDA)…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!